132 related articles for article (PubMed ID: 38417531)
1. The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants.
Ianevski A; Frøysa IT; Lysvand H; Calitz C; Smura T; Schjelderup Nilsen HJ; Høyer E; Afset JE; Sridhar A; Wolthers KC; Zusinaite E; Tenson T; Kurg R; Oksenych V; Galabov AS; Stoyanova A; Bjørås M; Kainov DE
Antiviral Res; 2024 Apr; 224():105842. PubMed ID: 38417531
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71.
Wang Y; Li G; Yuan S; Gao Q; Lan K; Altmeyer R; Zou G
Antimicrob Agents Chemother; 2016 Sep; 60(9):5357-67. PubMed ID: 27353263
[TBL] [Abstract][Full Text] [Related]
3. Automated cell-based luminescence assay for profiling antiviral compound activity against enteroviruses.
Zhang M; Zhang Y; Wang Y; Lv W; Zhang Y
Sci Rep; 2019 Apr; 9(1):6023. PubMed ID: 30988314
[TBL] [Abstract][Full Text] [Related]
4. Novel Synergistic Anti-Enteroviral Drug Combinations.
Ianevski A; Zusinaite E; Tenson T; Oksenych V; Wang W; Afset JE; Bjørås M; Kainov DE
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146673
[No Abstract] [Full Text] [Related]
5. Antiviral Peptides Targeting the Helicase Activity of Enterovirus Nonstructural Protein 2C.
Fang Y; Wang C; Wang C; Yang R; Bai P; Zhang XY; Kong J; Yin L; Qiu Y; Zhou X
J Virol; 2021 May; 95(12):. PubMed ID: 33789997
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of an isoxazole-3-carboxamide analog of pleconaril in mouse models of Enterovirus-D68 and Coxsackie B5.
Lane TR; Fu J; Sherry B; Tarbet B; Hurst BL; Riabova O; Kazakova E; Egorova A; Clarke P; Leser JS; Frost J; Rudy M; Tyler KL; Klose T; Volobueva AS; Belyaevskaya SV; Zarubaev VV; Kuhn RJ; Makarov V; Ekins S
Antiviral Res; 2023 Aug; 216():105654. PubMed ID: 37327878
[TBL] [Abstract][Full Text] [Related]
7. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication.
Tijsma A; Franco D; Tucker S; Hilgenfeld R; Froeyen M; Leyssen P; Neyts J
Antimicrob Agents Chemother; 2014 Nov; 58(11):6990-2. PubMed ID: 25199773
[TBL] [Abstract][Full Text] [Related]
8. Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection.
Zhang XN; Song ZG; Jiang T; Shi BS; Hu YW; Yuan ZH
World J Gastroenterol; 2010 Jan; 16(2):201-9. PubMed ID: 20066739
[TBL] [Abstract][Full Text] [Related]
9. The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.
Rocha-Pereira J; Nascimento MS; Ma Q; Hilgenfeld R; Neyts J; Jochmans D
Antimicrob Agents Chemother; 2014 Aug; 58(8):4675-81. PubMed ID: 24890597
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93.
Costenaro L; Kaczmarska Z; Arnan C; Janowski R; Coutard B; Solà M; Gorbalenya AE; Norder H; Canard B; Coll M
J Virol; 2011 Oct; 85(20):10764-73. PubMed ID: 21835784
[TBL] [Abstract][Full Text] [Related]
11. New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3.
Schmidtke M; Wutzler P; Zieger R; Riabova OB; Makarov VA
Antiviral Res; 2009 Jan; 81(1):56-63. PubMed ID: 18840470
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68.
Sun L; Meijer A; Froeyen M; Zhang L; Thibaut HJ; Baggen J; George S; Vernachio J; van Kuppeveld FJ; Leyssen P; Hilgenfeld R; Neyts J; Delang L
Antimicrob Agents Chemother; 2015 Dec; 59(12):7782-5. PubMed ID: 26369972
[TBL] [Abstract][Full Text] [Related]
13. Pleconaril revisited: clinical course of chronic enteroviral meningoencephalitis after treatment correlates with in vitro susceptibility.
Wildenbeest JG; van den Broek PJ; Benschop KS; Koen G; Wierenga PC; Vossen AC; Kuijpers TW; Wolthers KC
Antivir Ther; 2012; 17(3):459-66. PubMed ID: 22293148
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 3D Human Intestinal Organoids as a Platform for EV-A71 Antiviral Drug Discovery.
Masmoudi F; Santos-Ferreira N; Pajkrt D; Wolthers KC; DeGroot J; Vlaming MLH; Rocha-Pereira J; Buti L
Cells; 2023 Apr; 12(8):. PubMed ID: 37190047
[TBL] [Abstract][Full Text] [Related]
15. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.
Mello C; Aguayo E; Rodriguez M; Lee G; Jordan R; Cihlar T; Birkus G
Antimicrob Agents Chemother; 2014; 58(3):1546-55. PubMed ID: 24366736
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of inhibitors against 3C protease of coxsackievirus A16 and enterovirus A71 causing hand, foot and mouth disease: A molecular dynamics study.
Jetsadawisut W; Nutho B; Meeprasert A; Rungrotmongkol T; Kungwan N; Wolschann P; Hannongbua S
Biophys Chem; 2016 Dec; 219():9-16. PubMed ID: 27668727
[TBL] [Abstract][Full Text] [Related]
17. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design.
Lu G; Qi J; Chen Z; Xu X; Gao F; Lin D; Qian W; Liu H; Jiang H; Yan J; Gao GF
J Virol; 2011 Oct; 85(19):10319-31. PubMed ID: 21795339
[TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.
Smee DF; Evans WJ; Nicolaou KC; Tarbet EB; Day CW
Antiviral Res; 2016 Jul; 131():61-5. PubMed ID: 27063860
[TBL] [Abstract][Full Text] [Related]
19. Activity of pleconaril against enteroviruses.
Pevear DC; Tull TM; Seipel ME; Groarke JM
Antimicrob Agents Chemother; 1999 Sep; 43(9):2109-15. PubMed ID: 10471549
[TBL] [Abstract][Full Text] [Related]
20. The enteroviruses: problems in need of treatments.
Abzug MJ
J Infect; 2014 Jan; 68 Suppl 1():S108-14. PubMed ID: 24119825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
